ArticleFrontiers in microbiology2014
Emergence of Escherichia coli producing extended-spectrum AmpC β-lactamases (ESAC) in animals.
Article in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- Characterization of the intrinsic AmpC β-lactamase of Escherichia marmotae and its impact on decreased susceptibility to cefiderocol and resistance to broad-spectrum cephalosporins.The Journal of antimicrobial chemotherapy · 2026Article
- Changes in fecal microbiota after therapeutic exposure to amoxicillin-clavulanic acid in veal calves receiving multiple antibiotics.Microbiology spectrum · 2025Article
- On the Difficulty to Detect Carbapenem Resistance in the Environment: Characterisation of Escherichia coli With Reduced Carbapenem Susceptibility Isolated in a French River.Environmental microbiology reports · 2025Article
- Advances in drug resistance and resistance mechanisms of four colorectal cancer-associated gut microbiota.PeerJ · 2025Review
- Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance.Nature communications · 2024Article
- Designing of fragment based inhibitors with improved activity againstSaudi journal of biological sciences · 2024Article
- Article
- Class C β-Lactamases: Molecular Characteristics.Clinical microbiology reviews · 2022Review
- Antimicrobial drug resistance against Escherichia coli and its harmful effect on animal health.Veterinary medicine and science · 2022Review
- Systematic Review of Plasmid AmpC Type Resistances inMicroorganisms · 2022Article
- Prevalence and distribution of extended-spectrum β-lactamase and AmpC-producingFrontiers in microbiology · 2022Article
- Prevalence and Characterization of ESBL/AmpC ProducingAntibiotics (Basel, Switzerland) · 2021Article
- Genetic basis of molecular mechanisms in β-lactam resistant gram-negative bacteria.Microbial pathogenesis · 2021Review
- Characterization of a Novel Chromosome-Encoded AmpC β-Lactamase Gene,Frontiers in microbiology · 2021Article
- Article
- GradualFrontiers in microbiology · 2019Article
- Antibiotic-Resistant Pathogenic Escherichia Coli Isolated from Rooftop Rainwater-Harvesting Tanks in the Eastern Cape, South Africa.International journal of environmental research and public health · 2018Article
- Prevalence and Characterization of Multi-Drug-Resistant Gram-Negative Bacilli Isolated From Lebanese Poultry: A Nationwide Study.Frontiers in microbiology · 2018Article
- Prevalence and Emergence of Extended-Spectrum Cephalosporin-, Carbapenem- and Colistin-Resistant Gram Negative Bacteria of Animal Origin in the Mediterranean Basin.Frontiers in microbiology · 2018Review
- Development of a Rapid Reverse Blot Hybridization Assay for Detection of Clinically Relevant Antibiotic Resistance Genes in Blood Cultures Testing Positive for Gram-Negative Bacteria.Frontiers in microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In both humans and animals, the spread of Extended-Spectrum β-Lactamases (ESBL)/AmpC producers has become a major issue, particularly due to the plasmidic dissemination of most of these genes. Besides, over-expression of the chromosomal ampC gene was largely reported in human and animal Enterobacteriaceae and, more recently, modifications within the coding region of the ampC gene [encoding Extended-spectrum AmpC β-lactamases (ESACs)] were shown to be responsible for an hydrolysis spectrum expanded to oxyiminocephalosporins in humans. In this study, among 6765 cattle E. coli isolates, 28 (0.37%) isolates harboring a reduced susceptibility to cefepime (MICs ranging from 0.5 to 12 μg/ml) were investigated as presumptive ESACs producers. Highly conserved mutations in the promoter/attenuator region were identified at positions -88, -82, -42, -18, -1, and +58. Using sequencing and cloning experiments, amino acid substitutions of the AmpC beta-lactamase were characterized at positions 287 (mostly S287N, but also S287C), 292 (A292V) and 296 (H296P), similarly to data reported in humans. Interestingly, those cattle ESAC-producing E. coli isolates predominantly belonged to the Clonal Complex (CC) 23, thus mirroring what has been described in humans. The driving forces for the selection of ESACs in animals are unknown, and their prevalence needs to be further investigated in the different animal sectors. Considering the over-representation of ESAC-producing E. coli belonging to CC23 in both humans and animals, exchanges of ESAC producers between the two populations may have occurred as well. To our best knowledge, this study is the first report of ESACs in animals worldwide, which should be considered an emerging mechanism contributing to the resistance to extended-spectrum cephalosporins in the animal population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.